Literature DB >> 15765229

[Cognitive dysfunctions in multiple sclerosis patients].

C Engel1, B Greim, U K Zettl.   

Abstract

Cognitive dysfunctions are frequent symptoms of multiple sclerosis (MS) and occur in up to 65% of patients. Especially memory, attention, executive and visual constructive functions are impaired. These problems strongly affect patients' ability to work, social relationships, and quality of life. Symptoms of physical disabilities can arise independently. Cognitive dysfunctions are clear indicators of MS progression, since they represent highly complex functions depending on the integrity of neuronal networks. Once manifested after a relapse, they remain stable. Given a differentiating diagnosis, it is possible to treat these dysfunctions by cognitive training and pharmacologically for example by immunomodulating drugs. However, treatment options are limited at present. This report provides a detailed description of cognitive functions and performance in MS patients, their comorbidities such as fatigue and depression, currently available diagnostic tools, and therapeutic options.

Entities:  

Mesh:

Year:  2005        PMID: 15765229     DOI: 10.1007/s00115-005-1901-1

Source DB:  PubMed          Journal:  Nervenarzt        ISSN: 0028-2804            Impact factor:   1.214


  89 in total

1.  Fatigue in multiple sclerosis: a comparison of different rating scales and correlation to clinical parameters.

Authors:  P Flachenecker; T Kümpfel; B Kallmann; M Gottschalk; O Grauer; P Rieckmann; C Trenkwalder; K V Toyka
Journal:  Mult Scler       Date:  2002-12       Impact factor: 6.312

2.  Paced auditory serial-addition task: a measure of recovery from concussion.

Authors:  D M Gronwall
Journal:  Percept Mot Skills       Date:  1977-04

3.  Development of a rating scale for primary depressive illness.

Authors:  M Hamilton
Journal:  Br J Soc Clin Psychol       Date:  1967-12

4.  Depressed mood in multiple sclerosis: relationship to capacity-demanding memory and attentional functioning.

Authors:  P A Arnett; C I Higginson; W D Voss; B Wright; W I Bender; J M Wurst; J M Tippin
Journal:  Neuropsychology       Date:  1999-07       Impact factor: 3.295

5.  A longitudinal study of brain atrophy and cognitive disturbances in the early phase of relapsing-remitting multiple sclerosis.

Authors:  R Zivadinov; J Sepcic; D Nasuelli; R De Masi; L M Bragadin; M A Tommasi; S Zambito-Marsala; R Moretti; A Bratina; M Ukmar; R S Pozzi-Mucelli; A Grop; G Cazzato; M Zorzon
Journal:  J Neurol Neurosurg Psychiatry       Date:  2001-06       Impact factor: 10.154

6.  Working memory impairment in early multiple sclerosis. Evidence from an event-related potential study of patients with clinically isolated myelopathy.

Authors:  L Pelosi; J M Geesken; M Holly; M Hayward; L D Blumhardt
Journal:  Brain       Date:  1997-11       Impact factor: 13.501

Review 7.  The neuropsychiatry of multiple sclerosis.

Authors:  Anthony Feinstein
Journal:  Can J Psychiatry       Date:  2004-03       Impact factor: 4.356

8.  Neuropsychiatric assessment as a secondary outcome measure in a multiple sclerosis intravenous immunoglobulin L(IMg) trial.

Authors:  Y Barak; U Gabbay; R Glad; I Sarova-Pinhas; A Achiron
Journal:  Int J Psychiatry Clin Pract       Date:  1999       Impact factor: 1.812

9.  Relation between MR abnormalities and patterns of cognitive impairment in multiple sclerosis.

Authors:  M Rovaris; M Filippi; M Falautano; L Minicucci; M A Rocca; V Martinelli; G Comi
Journal:  Neurology       Date:  1998-06       Impact factor: 9.910

10.  Cognitive performance and MR markers of cerebral injury in cognitively impaired MS patients.

Authors:  C Christodoulou; L B Krupp; Z Liang; W Huang; P Melville; C Roque; W F Scherl; T Morgan; W S MacAllister; L Li; L A Tudorica; X Li; P Roche; R Peyster
Journal:  Neurology       Date:  2003-06-10       Impact factor: 9.910

View more
  3 in total

Review 1.  [Effects of high-dose cortisone therapy on cognition].

Authors:  I Uttner; H Tumani
Journal:  Nervenarzt       Date:  2006-06       Impact factor: 1.214

Review 2.  Influences on cognition by immunosuppression and immunomodulation in multiple sclerosis.

Authors:  Hayrettin Tumani; Ingo Uttner
Journal:  J Neurol       Date:  2007-05       Impact factor: 4.849

Review 3.  Diagnostics of cognitive dysfunctions in multiple sclerosis.

Authors:  Claudia Engel; Brigitte Greim; Uwe K Zettl
Journal:  J Neurol       Date:  2007-05       Impact factor: 4.849

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.